中国组织工程研究

中国组织工程研究 ›› 2011, Vol. 15 ›› Issue (24): 4437-4439.doi: 10.3969/j.issn.1673-8225.2011.24.016

• 组织构建与生物活性因子 tissue construction and bioactive factors • 上一篇    下一篇

灯盏花素对腹膜透析液诱导人腹膜间皮细胞转化生长因子β1的影响

杜  飞1，张克非1，高  原2，张文辉1，袁立英1   

  1. 1遵义医学院第三附属医院肾内科，贵州省遵义市 563000
    2遵义医学院珠海校区生理学教研室，广东省珠海市 519041
  • 收稿日期:2010-11-01 修回日期:2011-01-31 出版日期:2011-06-11 发布日期:2011-06-11
  • 作者简介:杜飞★，男，1980年生，贵州省凤岗县人，仡佬族，2007年遵义医学院毕业，硕士，主治医师，主要从事慢性肾脏疾病的研究。 feifei632@ yahoo.com.cn
  • 基金资助:

    贵州省卫生厅优秀医学青年人才基金(No.gzwkj2009-2-009)。

Effect of breviscapine on transforming growth factor beta 1 in human peritoneal mesothelial cells induced by peritoneal dialysis solution

Du Fei1, Zhang Ke-fei1, Gao Yuan2, Zhang Wen-hui1, Yuan Li-ying1   

  1. 1Department of Nephrology, the Third Affiliated Hospital of Zunyi Medical College, Zunyi  563000, Guizhou Province, China
    2Department of Physiology, Zhuhai Campus of Zunyi Medical College, Zhuhai  519041, Guangdong Province, China
  • Received:2010-11-01 Revised:2011-01-31 Online:2011-06-11 Published:2011-06-11
  • About author:Du Fei★, Master, Attending physician, Department of Nephrology, the Third Affiliated Hospital of Zunyi Medical College, Zunyi 563000, Guizhou Province, China feifei632@yahoo. com.cn
  • Supported by:

    Foundation for Excellent Young Talents in Medicine from Guizhou Provincial Health Committee, No. gzwkj2009-2-009*

PDF

420

摘要：

背景：从不同层面了解灯盏花素阻止/延缓腹膜功能衰竭的作用及其机制，从而在临床上推广使用灯盏花素来阻止/延缓腹膜功能衰竭从而延长终末期肾脏病患者腹膜透析时间、提高透析质量、减少透析失败率，提高腹膜透析远期疗效具有广泛的应用前景。
目的：观察灯盏花素对腹膜透析液诱导的人腹膜间皮细胞转化生长因子β1分泌及其增殖活性的影响。
方法：体外培养人腹膜间皮细胞，分为5组：分别为对照组、腹膜透析液组、灯盏花素终浓度为5，10，20 µmol/L组。检测各组上清液中转化生长因子β1的水平以及间皮细胞的增殖活性。
结果与结论：腹膜间皮细胞在腹膜透析液诱导下，转化生长因子β1分泌显著增加、细胞增殖活性显著降低。灯盏花素5 µmol/L组转化生长因子β1分泌低于腹膜透析液组(P < 0.05)，细胞增殖活性高于腹膜透析液组(P < 0.05)；灯盏花素10，20 µmol/L组转化生长因子β1分泌显著低于腹膜透析液组(P < 0.01)，细胞增殖活性显著高于腹膜透析液组(P < 0.01)。结果显示灯盏花素可以抑制腹膜间皮细胞转化生长因子β1分泌，拮抗腹膜透析液对腹膜间皮细胞增殖活性的抑制作用。

关键词: 腹膜透析, 腹膜间皮细胞, 灯盏花素, 细胞增殖, 转化生长因子&beta, 1

Abstract:

BACKGROUND: Based on the understanding of breviscapine effects and mechanism on inhibiting and delaying peritoneal failure, breviscapine is expected to be widely introduced to prolong peritoneal dialysis time, improve the quality of dialysis, and reduce dialysis failure rate so as to promote long-term effect of peritoneal dialysis in patients with end stage renal diseases.
OBJECTIVE: To observe the effects of breviscapine on the secretion of transforming growth factor beta 1 (TGF-β1) and proliferation activity of human peritoneal mesothelial cells (HPMCs) cultured in vitro with peritoneal dialysis solution (PDS).
METHODS: HPMCs were cultured in vitro and divided into five groups: control group, PDS group, 5 µmol/L breviscapine group, 10 µmol/L breviscapine group, and 20 µmol/L breviscapine group. The levels of TGF-β1 and proliferation of HPMCs in supernatant were detected and compared.
RESULTS AND CONCLUSION: Significantly increased levels of TGF-β1 and decreased cell proliferation activity were observed in the PDS group. The level of TGF-β1 in the PDS group was higher than that in the 5 µmol/L breviscapine group (P < 0.05), and significantly higher than that in the 10 µmol/L breviscapine group and 20 µmol/L breviscapine group (P < 0.01). The proliferation activity in the PDS group was lower than that in the 5 µmol/L breviscapine group (P < 0.05), and significantly lower than that in the 10 µmol/L breviscapine group and 20 µmol/L breviscapine group (P < 0.01). The results indicated that breviscapine can reduce the secretion of TGF-β1 in cultured HPMCs. Also it can restore the reduced cell proliferation activity caused by PDS．

中图分类号: